Related Experiment Video
Updated: Sep 9, 2026
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Potassium-Competitive Acid Blockers for First-Line Helicobacter pylori Eradication: A Systematic Review and
Constance A Kovarbasic1, Camille El Khiati1,2, Hannah C Knölker1
1School of Health Sciences, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain.
Background And Aims:
Potassium-competitive acid blockers (P-CABs) have emerged as an alternative to proton pump inhibitors (PPIs) for Helicobacter pylori eradication. However, much of the available evidence is based on comparisons with suboptimal PPI-based regimens. We conducted a systematic review and meta-analysis to compare P-CAB-based regimens with bismuth-containing PPI (B-PPI)-based quadruple therapies as first-line treatment for H pylori eradication.
Methods:
A systematic search of PubMed, ScienceDirect, Cochrane, and Scopus databases was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Randomized controlled trials comparing P-CAB-based regimens with B-PPI-based quadruple therapies were included. Pooled risk ratios (RRs) were calculated. The primary outcome was the eradication rate; secondary outcomes were treatment compliance and subgroup analysis according to the specific P-CAB used.
Results:
Twenty-five trials including 8789 patients were analyzed. In the intention-to-treat analysis, pooled eradication rates were 86.8% for P-CAB-based regimens and 83.3% for PPI-based quadruple therapy (RR: 1.04; 95% confidence interval [CI]: 1.01-1.07; P = .005). In the per-protocol analysis, no statistical significance was observed (89.4% vs 88.5%; RR: 1.02; 95% CI: 0.99-1.05; P = .17). Treatment compliance was similar between groups (92.6% vs 91.3%; RR: 1.01; 95% CI: 0.99-1.02; P = .40). In subgroup analyses, no significant differences were confirmed for individual P-CABs.
Conclusion:
Compared with B-PPI-based quadruple therapy, P-CAB-based regimens showed a small statistical advantage in intention-to-treat analysis, which was not consistently supported by per-protocol or subgroup analyses. No difference in treatment adherence was observed. These findings suggest that P-CAB-based regimens should be considered alternative first-line options rather than clear replacements for standard PPI-based quadruple therapy.
More Related Videos
06:40Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance
Published on: July 28, 2023
04:56Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
Published on: May 16, 2025
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:31Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors